Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome

    loading  Checking for direct PDF access through Ovid

Abstract

Transient headache exacerbation during IV dihydroergotamine (DHE) therapy of migraine may prompt clinicians to prematurely discontinue DHE therapy, potentially depriving patients of the full benefit of DHE infusion. In a recent Neurology® article, Eller et al. evaluated whether or not worsening headache during DHE infusion was associated with suboptimal medium-term headache outcomes.

Related Topics

    loading  Loading Related Articles